DNA vaccines expressing pneumococcal surface protein A (PspA) elicit protection levels comparable to recombinant protein.

Pneumococcal surface protein A (PspA) is a promising candidate for the development of cost-effective vaccines against Streptococcus pneumoniae. In the present study, BALB/c mice were immunized with DNA vaccine vectors expressing the N-terminal region of PspA. Animals immunized with a vector expressing secreted PspA developed higher levels of antibody than mice immunized with the vector expressing the antigen in the cytosol. However, both immunogens elicited similar levels of protection against intraperitoneal challenge. Furthermore, immunization with exactly the same fragment in the form of a recombinant protein, with aluminium hydroxide as an adjuvant, elicited even higher antibody levels, but this increased humoral response did not correlate with enhanced protection. These results show that DNA vaccines expressing PspA are able to elicit protection levels comparable to recombinant protein, even though total anti-PspA IgG response is considerably lower.

[1]  D. Briles,et al.  PspA Protects Streptococcus pneumoniae from Killing by Apolactoferrin, and Antibody to PspA Enhances Killing of Pneumococci by Apolactoferrin , 2004, Infection and Immunity.

[2]  E. Miyaji,et al.  Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice. , 2004, Biochemical and biophysical research communications.

[3]  P. Ho,et al.  A high-copy T7 Escherichia coli expression vector for the production of recombinant proteins with a minimal N-terminal His-tagged fusion peptide. , 2004, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[4]  R. de Groot,et al.  Pneumococcal vaccines: an update on current strategies. , 2004, Vaccine.

[5]  D. Briles,et al.  Effects of PspA and Antibodies to PspA on Activation and Deposition of Complement on the Pneumococcal Surface , 2004, Infection and Immunity.

[6]  N. Haigwood,et al.  DNA vaccine strategies: candidates for immune modulation and immunization regimens. , 2003, Methods.

[7]  E. Miyaji,et al.  Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses. , 2003, FEMS immunology and medical microbiology.

[8]  M. Brandileone,et al.  Appropriateness of a pneumococcal conjugate vaccine in Brazil: potential impact of age and clinical diagnosis, with emphasis on meningitis. , 2003, The Journal of infectious diseases.

[9]  K. O'Brien,et al.  Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. , 2003, Vaccine.

[10]  M. Brandileone,et al.  Analysis of Serum Cross-Reactivity and Cross-Protection Elicited by Immunization with DNA Vaccines against Streptococcus pneumoniae Expressing PspA Fragments from Different Clades , 2002, Infection and Immunity.

[11]  B. Arulanandam,et al.  Intranasal Vaccination with Pneumococcal Surface Protein A and Interleukin-12 Augments Antibody-Mediated Opsonization and Protective Immunity against Streptococcus pneumoniae Infection , 2001, Infection and Immunity.

[12]  E. Swiatlo,et al.  Genetic Immunization with the Region Encoding the α-Helical Domain of PspA Elicits Protective Immunity againstStreptococcus pneumoniae , 2001, Infection and Immunity.

[13]  M. Avison,et al.  Interscience Conference on Antimicrobial Agents and Chemotherapy , 2001 .

[14]  D. Briles,et al.  Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. , 2000, The Journal of infectious diseases.

[15]  D. Briles,et al.  The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. , 2000, Vaccine.

[16]  D. Briles,et al.  Pneumococcal Surface Protein A Inhibits Complement Activation by Streptococcus pneumoniae , 1999, Infection and Immunity.

[17]  J. Eskola,et al.  Pneumococcal conjugate vaccines. , 1999, The Pediatric infectious disease journal.

[18]  C. Harding,et al.  CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity , 1997, The Journal of experimental medicine.

[19]  D. Klinman,et al.  Contribution of CpG motifs to the immunogenicity of DNA vaccines. , 1997, Journal of immunology.

[20]  F. Loechel,et al.  Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae , 1997, Gene Therapy.